Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

The global weight-loss drug market is expected to reach $150 billion in the next decade. By 2026, semaglutide (the active ...

Eli Lilly launched its diabetes and weight-loss drug Mounjaro in India, ahead of Novo Nordisk, aiming at a market grappling ...

Another popular diabetes and weight-loss drug, Ozempic (semaglutide), manufactured by Novo Nordisk, has already established a ...

The drug will be priced at ₹3,500 for a 2.5 mg vial and ₹4,375 for the 5 mg vial. The injectable, to be taken once a week, ...

US pharma giant Eli Lilly's Mounjaro can prove crucial in treatment of obesity & type 2 diabetes. Launched in the US in 2022, ...

Starting at Rs 3,500 per injection, with a monthly cost of up to Rs 14,000, Mounjaro enters India’s growing diabetes and ...

Eli Lilly has launched its diabetes and weight-loss drug Mounjaro in India following approval from the country's drug ...

Eli Lilly has launched Mounjaro in India, a new once-weekly injectable drug for type 2 diabetes and weight management.

Mounjaro, chemically known as tirzepatide, is currently sold in the UK and Europe under the same brand name for both diabetes ...

The single-dose vial presentation has marketing authorization from the national drugs regulator—Central Drugs Standard ...

The drug has seen strong demand in the US and Europe, and its India launch is part of Lilly’s broader strategy to expand ...